Is Dianthus Therapeutics Stock a Good Investment?
Dianthus Therapeutics Investment Advice | DNTH |
- Examine Dianthus Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Dianthus Therapeutics' leadership team and their track record. Good management can help Dianthus Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Dianthus Therapeutics' business and its evolving consumer preferences.
- Compare Dianthus Therapeutics' performance and market position to its competitors. Analyze how Dianthus Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Dianthus Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Dianthus Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Dianthus Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Dianthus Therapeutics is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Dianthus Therapeutics Stock
Researching Dianthus Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 92.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.77. Some equities with similar Price to Book (P/B) outperform the market in the long run. Dianthus Therapeutics recorded a loss per share of 2.55. The entity had not issued any dividends in recent years. The firm had 1:16 split on the 12th of September 2023.
To determine if Dianthus Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Dianthus Therapeutics' research are outlined below:
| Dianthus Therapeutics generated a negative expected return over the last 90 days | |
| Dianthus Therapeutics has high historical volatility and very poor performance | |
| Dianthus Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 6.24 M. Net Loss for the year was (84.97 M) with profit before overhead, payroll, taxes, and interest of 6.24 M. | |
| Dianthus Therapeutics generates negative cash flow from operations | |
| Dianthus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: Alnylam Surges 11.8 percent Is This an Indication of Further Gains |
Dianthus Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Dianthus Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dianthus Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Dianthus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Dianthus Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-08-04 | 2022-06-30 | -0.34 | -0.29 | 0.05 | 14 | ||
2021-08-05 | 2021-06-30 | -0.3725 | -0.32 | 0.0525 | 14 | ||
2020-11-05 | 2020-09-30 | -0.43 | -0.37 | 0.06 | 13 | ||
2020-08-06 | 2020-06-30 | -0.54 | -0.48 | 0.06 | 11 | ||
2023-05-11 | 2023-03-31 | -0.4 | -0.47 | -0.07 | 17 | ||
2022-05-16 | 2022-03-31 | -0.3181 | -0.39 | -0.0719 | 22 | ||
2020-05-07 | 2020-03-31 | -0.6 | -0.51 | 0.09 | 15 | ||
2024-05-09 | 2024-03-31 | -0.44 | -0.54 | -0.1 | 22 |
Dianthus Therapeutics Target Price Consensus
Dianthus target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Dianthus Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 12 | Strong Buy |
Most Dianthus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Dianthus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Dianthus Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationDianthus Therapeutics Target Price Projection
Dianthus Therapeutics' current and average target prices are 18.74 and 51.80, respectively. The current price of Dianthus Therapeutics is the price at which Dianthus Therapeutics is currently trading. On the other hand, Dianthus Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Dianthus Therapeutics Market Quote on 25th of March 2025
Target Price
Analyst Consensus On Dianthus Therapeutics Target Price
Dianthus Therapeutics Analyst Ratings
Dianthus Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Dianthus Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Dianthus Therapeutics' financials, market performance, and future outlook by experienced professionals. Dianthus Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Dianthus Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 623.55 M.Market Cap |
|
Dianthus Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.23) | (0.24) | |
| Return On Capital Employed | (0.29) | (0.30) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.24) | (0.25) |
Determining Dianthus Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Dianthus Therapeutics is a good buy. For example, gross profit margin measures Dianthus Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Dianthus Therapeutics' profitability and make more informed investment decisions.
Basic technical analysis of Dianthus Stock
As of the 25th of March, Dianthus Therapeutics shows the Standard Deviation of 4.77, mean deviation of 3.47, and Coefficient Of Variation of (2,258). Dianthus Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Dianthus Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dianthus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dianthus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dianthus Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dianthus Therapeutics' Outstanding Corporate Bonds
Dianthus Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Dianthus Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Dianthus bonds can be classified according to their maturity, which is the date when Dianthus Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand Dianthus Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Dianthus Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.14) | |||
| Mean Deviation | 3.47 | |||
| Coefficient Of Variation | (2,258) | |||
| Standard Deviation | 4.77 | |||
| Variance | 22.73 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (0.03) | |||
| Treynor Ratio | (0.15) | |||
| Maximum Drawdown | 21.99 | |||
| Value At Risk | (7.16) | |||
| Potential Upside | 8.28 | |||
| Skewness | 0.2289 | |||
| Kurtosis | 1.36 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.14) | |||
| Mean Deviation | 3.47 | |||
| Coefficient Of Variation | (2,258) | |||
| Standard Deviation | 4.77 | |||
| Variance | 22.73 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (0.03) | |||
| Treynor Ratio | (0.15) | |||
| Maximum Drawdown | 21.99 | |||
| Value At Risk | (7.16) | |||
| Potential Upside | 8.28 | |||
| Skewness | 0.2289 | |||
| Kurtosis | 1.36 |
Consider Dianthus Therapeutics' intraday indicators
Dianthus Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Dianthus Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 18.74 | |||
| Day Typical Price | 18.74 | |||
| Price Action Indicator | (0.34) | |||
| Period Momentum Indicator | (0.67) | |||
| Relative Strength Index | 44.47 |
Dianthus Therapeutics Corporate Filings
| 24th of March 2025 Other Reports | ViewVerify | |
| 19th of March 2025 Other Reports | ViewVerify | |
8K | 11th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
Dianthus Stock media impact
Far too much social signal, news, headlines, and media speculation about Dianthus Therapeutics that are available to investors today. That information is available publicly through Dianthus media outlets and privately through word of mouth or via Dianthus internal channels. However, regardless of the origin, that massive amount of Dianthus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Dianthus Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Dianthus Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Dianthus Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Dianthus Therapeutics alpha.
Dianthus Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Dianthus Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Dianthus Therapeutics Corporate Management
| Jennifer Ruff | VP Affairs | Profile | |
| Edward Carr | Chief Officer | Profile | |
| Kristina Maximenko | Chief Officer | Profile | |
| MD MBA | Chief Officer | Profile | |
| Adam Esq | General Counsel | Profile | |
| Judson Taylor | Senior Operations | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dianthus Therapeutics. If investors know Dianthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.55) | Revenue Per Share | Quarterly Revenue Growth 1.902 | Return On Assets | Return On Equity |
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Dianthus Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Dianthus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dianthus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.